Bharat Parenterals shares experienced their third consecutive session of gains on Friday, September 25, with the stock locked in a 20% upper circuit at its 52-week high of ₹1,895.10 on the BSE. According to market reports, on the National Stock Exchange, the stock surged by its daily maximum limit of 20% and touched its 52-week high of ₹1,898. As of 2:21 pm, there were pending buy orders for 10,127 shares while no seller was seen on the NSE, indicating heavy demand for the pharmaceutical company's shares.
The stock rally was triggered by Bharat Parenterals' announcement that its board will meet on Tuesday, September 29, 2026, to consider fund raising via preferential issuance of equity shares. As reported in the company's regulatory filing, the board meeting will evaluate and approve proposals for issuance of equity shares or other eligible securities by way of Preferential Issue, though the company did not disclose the amount it plans to raise. The company has also announced that trading in its securities by designated persons and their immediate relatives will remain closed till the expiry of 48 hours from the conclusion of the meeting.
According to the company's earnings release, Bharat Parenterals reported a significant decline in Q1 FY26 performance with net profit dropping 64% to ₹3.65 crore from ₹10 crore in the same period last year. The company's revenue from operations declined 42% to ₹55 crore at the end of June quarter compared to ₹94 crore in the year-ago period. As reported by the company, the revenue decline was attributed to base effect as Q1 FY26 was the largest revenue quarter in the company's history, equal to 40% of FY26 revenue of ₹234.0 crore and 61% above the FY26 quarterly average of ₹58.5 crore.
The company faced operational headwinds with EBITDA falling 61% to ₹6 crore from ₹15 crore and EBITDA margin contracting by 540 basis points to 10.8%. According to the earnings release, the company reported weak operational performance with the decline in revenue being due to base effect, as Q1 FY26 carried the opening tranche of the ₹210 crore institutional order (delivery spread over eighteen months starting April 2025) whose closing tranche fell in Q1 FY27.
